BioSyntech's BST-Gel Drug Delivery Program Exceeds Initial Expectations.Business Editors LAVAL, Quebec--(BUSINESS WIRE)--Feb. 5, 2002 BioSyntech, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BSYI), a developer of tissue repair therapies and revolutionary drug delivery platforms, today announced the Company's drug delivery development program, based on BioSyntech's BST-Gel platform, is progressing well ahead of internal expectations. Initial research using BioSyntech's BST-Gel and an anti-tumor molecule show promising in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. results in slowing the growth of tumors in mice. Using a mouse tumor tumor: see neoplasm. model, a Camptothecin formulation (an anti-cancer molecule) in the BST-Gel was implanted directly into the tumors. The growth of the tumors was shown to be significantly delayed in treated mice in comparison to the untreated mice, and no adverse effects were observed. Dr. A. Gupta, chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of BioSyntech, presented these results at the Sixth Annual U.S./Japan Drug Delivery Symposium in Hawaii in December. Following Dr. Gupta's presentations, a number of prominent pharmaceutical companies approached BioSyntech to discuss potential drug delivery studies with their existing molecules. "Based on these initial results, management remains excited about the potential of BioSyntech's BST-Gel drug delivery platform," said Dr. Gupta. "The drug delivery project presents a large and compelling opportunity for BioSyntech and opens new potential strategies for cancer chemotherapy. Further, we believe this method has potential for precisely targeting the delivery of other molecules using the BST-Gel." BioSyntech Inc. is an advanced biomaterials company specializing in tissue repair and in the delivery of biotherapeutic products. This press release contains certain "forward-looking" statements, as defined in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the company's filings with the regulatory authorities Noun 1. regulatory authority - a governmental agency that regulates businesses in the public interest regulatory agency administrative body, administrative unit - a unit with administrative responsibilities having jurisdiction. No regulatory authority has approved or disapproved the content of this release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion